RxDoctor Payments Data

John Palcheff, DO

Family Medicine · Jerseyville, ILNPI 1760442032

Payments from drug & device makers

$12,929in general payments, 2019–2025

Across 814 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • GSK$726
  • AstraZeneca$714
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$12,76199%
  • Education$1681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,929 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$11,122
Medicare patients
262
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate59$56,562
OzempicSemaglutide28$46,024
TrulicityDulaglutide33$45,291
JardianceEmpagliflozin47$43,576
Bydureon BciseExenatide Microspheres29$39,400
EliquisApixaban84$35,969
XareltoRivaroxaban19$26,224
Breo ElliptaFluticasone/Vilanterol45$23,207
InvokanaCanagliflozin19$22,301
MounjaroTirzepatide19$18,296
TradjentaLinagliptin32$17,708
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,607
EntrestoSacubitril/Valsartan16$11,634
BrilintaTicagrelor26$11,225
CreonLipase/Protease/Amylase13$9,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,379$63,58752 claims
Boehringer IngelheimJardiance, Tradjenta$196$61,28479 claims
MerckJanuvia$420$56,56259 claims
Johnson & JohnsonXarelto, Invokana$706$48,52538 claims
Novo NordiskOzempic$1,500$46,02428 claims
GSKBreo Ellipta, Trelegy Ellipta$726$39,81370 claims
PfizerEliquis$573$35,96984 claims
AbbVieCreon, Namzaric$1,712$15,50232 claims
NovartisEntresto$257$11,63416 claims
AstraZenecaBrilinta$714$11,22526 claims
Sanofi-aventis U.S. LLCRenvela$240$2,54711 claims
Almatica Pharma LLCSertraline Hcl$52$1,83195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Jerseyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →